Prostatype Genomics AB (publ)
Prostatype Genomics AB manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doctors whe… Read more
Market Cap & Net Worth: Prostatype Genomics AB (publ) (PGABF)
Prostatype Genomics AB (publ) (OTCQB:PGABF) has a market capitalization of $3.47K ($3.47K) as of March 18, 2026. Listed on the OTCQB stock exchange, this USA-based company holds position #46571 globally and #14498 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Prostatype Genomics AB (publ)'s stock price $0.36 by its total outstanding shares 9688 (9.69K).
Prostatype Genomics AB (publ) Market Cap History: 2025 to 2025
Prostatype Genomics AB (publ)'s market capitalization history from 2025 to 2025. Data shows growth from $3.47K to $3.47K (0.00% CAGR).
Prostatype Genomics AB (publ) Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Prostatype Genomics AB (publ)'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PGABF by Market Capitalization
Companies near Prostatype Genomics AB (publ) in the global market cap rankings as of March 18, 2026.
Key companies related to Prostatype Genomics AB (publ) by market ranking:
- E-finance For Digital and Financial Investments (EGX:EFIH): Ranked #46562 globally with a market cap of $3.42K USD ( EGP172.89K EGP).
- 10 Yr Variable Rate (KAR:P10VRR211034): Ranked #46563 globally with a market cap of $3.42K USD ( PKRs952.51K PKR).
- HAGA3F (SA:HAGA3F): Ranked #46572 globally with a market cap of $3.40K USD ( R$20.70K BRL).
- Galvo (WAR:GAL): Ranked #46573 globally with a market cap of $3.40K USD ( zł14.12K PLN).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #46562 | E-finance For Digital and Financial Investments | EGX:EFIH | $3.42K | EGP18.40 |
| #46563 | 10 Yr Variable Rate | KAR:P10VRR211034 | $3.42K | PKRs102.52 |
| #46572 | HAGA3F | SA:HAGA3F | $3.40K | R$2.21 |
| #46573 | Galvo | WAR:GAL | $3.40K | zł1.48 |
Prostatype Genomics AB (publ) Historical Marketcap From 2025 to 2025
Between 2025 and today, Prostatype Genomics AB (publ)'s market cap moved from $3.47K to $ 3.47K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $3.47K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Prostatype Genomics AB (publ) was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.47K USD |
| MoneyControl | $3.47K USD |
| MarketWatch | $3.47K USD |
| marketcap.company | $3.47K USD |
| Reuters | $3.47K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.